Antiviral agent 35_product_DataBase

Bioactivity	Antiviral agent 35 (compound 4d) is an orally active and potent influenza virus inhibitor, acting function in the early stage of virus replication. Antiviral agent 35 inhibits ROS accumulation, autophagy and apoptosis induced by influenza virus, and also inhibits inflammatory response mediated by RIG-1 pathway in mouse model with pulmonary infection. Antiviral agent 35 shows little cytotoxicity with CC50 >800 μM in MDCK cells, and anti-H1N1 (A/Weiss/43) activity with EC50 of 2.28 μM[1].
Target	EC50: 2.28 μM (HINI A/Weiss/43), 3.34 μM (A/Virginia/ATCC2/2009), 6.61 μM (A/Califomia/2014)
Invitro	Antiviral agent 35 (compound 4d) (25 μM, 50 μM; 24-72 h) 抑制 MDCK 细胞中的流感病毒复制[1]。 0 --> Antiviral agent 35 相关抗体:
In Vivo	Antiviral agent 35 (compound 4d) (25 mg/kg/d, 50 mg/kg/d, 100 mg/kg/d; by gavage; 2-6 d) 在 H1N1 感染后的第 2、4 和 6 天减轻小鼠的肺部炎症[1]。
Name	Antiviral agent 35
CAS	2760972-52-7
Formula	C23H18N2O4S
Molar Mass	418.47
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Ge Y, et al. Synthesis and pharmacodynamic evaluation of naphthalene derivatives against influenza A virus in vitro and in vivo. Eur J Med Chem. 2023 Nov 5;259:115660.

PeptideDB